Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Monk

Showing results (81-90 of 738) with videos related to

Pageof 74
Sort By:
Gynecologic Oncology|February 6, 2007
Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trialsBradley J Monk, Chunqiao Tian, Peter G Rose, et al.
Current Oncology Reports|October 16, 2004
Cervical cancer screeningDorothy J Wiley, Bradley J Monk, Emmanuel Masongsong, et al.
Pharmaceuticals (Basel, Switzerland)|January 31, 2017
Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician SurveyBradley J Monk, Philip E Lammers, Thomas Cartwright, et al.
Journal of Virology|June 1, 1992
Direct determination of the point mutation rate of a murine retrovirusR J Monk, F G Malik, D Stokesberry, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 8, 2007
Wnt signaling in ovarian tumorigenesisT A Gatcliffe, B J Monk, K Planutis, et al.
Obstetrics and Gynecology|September 1, 1992
Natural history of the minimally abnormal Papanicolaou smearF J Montz, B J Monk, J M Fowler, et al.
Gynecologic Oncology|August 7, 2004
Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupFranco M Muggia, John A Blessing, Ramon McGehee, et al.
Gynecologic Oncology|February 22, 2005
Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancerBradley J Monk, David C Choi, Gordon Pugmire, et al.
European Journal of Gynaecological Oncology|January 1, 1993
Radical hysterectomy after pelvic irradiation in patients with high risk cervical cancer or uterine sarcoma: morbidity and outcomeB J Monk, S Solh, M T Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2005
Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group StudyBradley J Monk, Helen Q Huang, David Cella, et al.
Pageof 74

Showing results (81-90 of 738) with videos related to

Sort By:
Pageof 74
Gynecologic Oncology|February 6, 2007
Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trialsBradley J Monk, Chunqiao Tian, Peter G Rose, et al.
Current Oncology Reports|October 16, 2004
Cervical cancer screeningDorothy J Wiley, Bradley J Monk, Emmanuel Masongsong, et al.
Pharmaceuticals (Basel, Switzerland)|January 31, 2017
Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician SurveyBradley J Monk, Philip E Lammers, Thomas Cartwright, et al.
Journal of Virology|June 1, 1992
Direct determination of the point mutation rate of a murine retrovirusR J Monk, F G Malik, D Stokesberry, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 8, 2007
Wnt signaling in ovarian tumorigenesisT A Gatcliffe, B J Monk, K Planutis, et al.
Obstetrics and Gynecology|September 1, 1992
Natural history of the minimally abnormal Papanicolaou smearF J Montz, B J Monk, J M Fowler, et al.
Gynecologic Oncology|August 7, 2004
Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupFranco M Muggia, John A Blessing, Ramon McGehee, et al.
Gynecologic Oncology|February 22, 2005
Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancerBradley J Monk, David C Choi, Gordon Pugmire, et al.
European Journal of Gynaecological Oncology|January 1, 1993
Radical hysterectomy after pelvic irradiation in patients with high risk cervical cancer or uterine sarcoma: morbidity and outcomeB J Monk, S Solh, M T Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2005
Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group StudyBradley J Monk, Helen Q Huang, David Cella, et al.
Pageof 74